Targeting FLT3 mutations in AML: review of current knowledge and evidence
Genomic investigations of acute myeloid leukemia (AML) have demonstrated that several
genes are recurrently mutated, leading to new genomic classifications, predictive …
genes are recurrently mutated, leading to new genomic classifications, predictive …
FMS-like tyrosine kinase 3/FLT3: from basic science to clinical implications
JU Kazi, L Rönnstrand - Physiological reviews, 2019 - journals.physiology.org
FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase that is expressed almost
exclusively in the hematopoietic compartment. Its ligand, FLT3 ligand (FL), induces …
exclusively in the hematopoietic compartment. Its ligand, FLT3 ligand (FL), induces …
Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation
RF Schlenk, S Kayser, L Bullinger… - Blood, The Journal …, 2014 - ashpublications.org
The objective was to evaluate the prognostic and predictive impact of allelic ratio and
insertion site (IS) of internal tandem duplications (ITDs), as well as concurrent gene …
insertion site (IS) of internal tandem duplications (ITDs), as well as concurrent gene …
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute …
An internal tandem duplication in the fms-like tyrosine kinase 3 gene (FLT3/ITD) is
associated with poor prognosis in acute myeloid leukemia (AML), but the impact of mutant …
associated with poor prognosis in acute myeloid leukemia (AML), but the impact of mutant …
FLT3 as a therapeutic target in AML: still challenging after all these years
Mutations within the FMS-like tyrosine kinase 3 (FLT3) gene on chromosome 13q12 have
been detected in up to 35% of acute myeloid leukemia (AML) patients and represent one of …
been detected in up to 35% of acute myeloid leukemia (AML) patients and represent one of …
Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized …
Recent molecular analyses of leukemic blasts from pretreatment marrow or blood of patients
with acute myeloid leukemia (AML) and a normal karyotype, the largest cytogenetic subset …
with acute myeloid leukemia (AML) and a normal karyotype, the largest cytogenetic subset …
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3‐ITD acute myeloid leukaemia in first complete remission
We performed a retrospective study analysing the effect of sorafenib, an oral fms‐Like
Tyrosine Kinase 3 (FLT 3)/multikinase inhibitor, as post‐transplant maintenance in adult …
Tyrosine Kinase 3 (FLT 3)/multikinase inhibitor, as post‐transplant maintenance in adult …
Gilteritinib: potent targeting of FLT3 mutations in AML
M Levis, AE Perl - Blood advances, 2020 - ashpublications.org
Since the discovery of FMS-like tyrosine kinase-3 (FLT3)–activating mutations as genetic
drivers in acute myeloid leukemia (AML), investigators have tried to develop tyrosine kinase …
drivers in acute myeloid leukemia (AML), investigators have tried to develop tyrosine kinase …
FLT3 inhibitors in acute myeloid leukemia: challenges and recent developments in overcoming resistance
Z Wang, J Cai, J Cheng, W Yang, Y Zhu… - Journal of Medicinal …, 2021 - ACS Publications
Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are often present in newly
diagnosed acute myeloid leukemia (AML) patients with an incidence rate of approximately …
diagnosed acute myeloid leukemia (AML) patients with an incidence rate of approximately …
Cooperating gene mutations in acute myeloid leukemia: a review of the literature
A Renneville, C Roumier, V Biggio, O Nibourel… - leukemia, 2008 - nature.com
Acute myeloid leukemia (AML) is a heterogeneous group of neoplastic disorders with great
variability in clinical course and response to therapy, as well as in the genetic and molecular …
variability in clinical course and response to therapy, as well as in the genetic and molecular …